Marex Group’s Acrivon Therapeutics ACRV Stock Holding History

Marex Group’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$17.8K	Sell	10,000 -10,000	-50%	-$17K	﹤0.01%	1103
2026 Q1	$27.8K	Buy	20,000 +10,000	+100%	+$17.4K	﹤0.01%	983
2025 Q4	$24.1K	Buy	+10,000	New	+$21.7K	﹤0.01%	944
2025 Q2	–	Sell	-14,080	Closed	-$28.6K	–	646
2025 Q1	$28.6K	Buy	14,080 +893	+7%	+$4.81K	﹤0.01%	656
2024 Q4	$79.4K	Hold	13,187	–	–	﹤0.01%	627
2024 Q3	$92.3K	Hold	13,187	–	–	﹤0.01%	542
2024 Q2	$76.5K	Buy	+13,187	New	+$106K	﹤0.01%	578
2024 Q1	–	Sell	-13,187	Closed	-$64.9K	–	486
2023 Q4	$64.9K	Buy	+13,187	New	+$69.7K	﹤0.01%	518

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marex Group's ACRV Position: Q2 2026 in Review

Marex Group reduced its Acrivon Therapeutics (ACRV) stake by 50% in Q2 2026, selling an estimated $17K and leaving 10,000 shares worth $17.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1103.

Marex Group first reported a position in ACRV in Q4 2023 and has held it in 8 quarters since. The position peaked at $92.3K in Q3 2024. 46 funds tracked by Wall St. Rank hold ACRV as of Q2 2026.

Marex Group held 10,000 shares of Acrivon Therapeutics worth $17.8K as of Q2 2026.
Marex Group sold 10,000 Acrivon Therapeutics shares in Q2 2026, an estimated $17K.
Acrivon Therapeutics made up ﹤0.01% of Marex Group's portfolio in Q2 2026, its #1103 holding.
Marex Group first reported a position in Acrivon Therapeutics in Q4 2023 and has held it in 8 quarters since.
Marex Group's Acrivon Therapeutics position peaked at $92.3K in Q3 2024.
46 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2026.

Based on Marex Group's 13F filing for Q2 2026, filed 14 Aug 2026.